SummaryThe conversation covers the published data from the IGNYTE study - RP1 + nivolumab: response rate and safety profile, RNA-seq analysis, and toxicity. The key takeaways include insights into clinical trial interpretation and treatment efficacy (and incorrect graphs).Takeaways

• Clinical Trial Data
• Treatment Efficacy

Chapters

• 00:00 Introduction to IGNYTE Study
• 14:04 Response Rate and Safety Profile
• 25:17 RNA-seq Analysis and Toxicity